Quantcast

G-Tech Obtains IRB Approval for Irritable Bowel Syndrome Clinical Study

September 29, 2012

G-Tech has obtained IRB approval to launch a clinical research study designed to record abnormal myoelectrical activity in subjects with irritable bowel syndrome (IBS).

Palo Alto, Calif. (PRWEB) September 28, 2012

G-Tech, an early stage medical device company, announced today that it has received IRB approval to launch a six-month, 60-subject clinical research study designed to record abnormal myoelectrical activity in subjects with abdominal pain associated with irritable bowel syndrome (IBS).

It is estimated that as many as 20 percent of Americans have significant digestive issues and GI-related complaints account for approximately 20 million doctor visits a year. Diagnostic procedures to determine the source of problems associated with IBS may include blood work, colonoscopy, CT scans, contrast enhanced X-rays and several motility related tests. Unfortunately, no clear cause of the problem is identified in nearly half of the cases because existing tests identify anatomic irregularities but not functional ones.

G-Tech´s unique diagnostic approach measures myoelectric signals from GI organs, in the same way an ECG (electrocardiogram) measures electrical signals in the heart. Published literature has established that the patterns of electric signals associated with organ activity differ between healthy subjects and those with GI disorders.

“The objective of this study is to measure the electrical signals at the skin surface and differentiate patterns of myoelectric activity in healthy subjects from the electrical patterns in symptomatic subjects,” said Steve Axelrod, Ph.D., G-Tech CEO. “By quantifying these differences, G-Tech will supply a powerful diagnostic tool useful to the millions of Americans afflicted with abdominal pain, constipation, diarrhea and bloating.” Accurate diagnosis may lead to more effective and targeted therapy resulting in a significant cost reduction due to reduced chronic office visits that can occur with patients with functional GI disorders such as IBS.

“I am very excited to be involved in this study to find a simple and non-invasive tool that would tell doctors that a patient has irritable bowel syndrome. This has the potential to avoid further tests and could reduce dramatically healthcare costs as reassured patients start treatment faster and more efficiently,” said George Triadafilopoulos, MD, Clinical Professor of Gastroenterology and Hepatology at Stanford University School of Medicine.

Enrollment in the trial will begin immediately in the San Francisco Bay Area.

About G-Tech Inc.

G-Tech Inc. is an early-stage medical device company dedicated to developing low-cost, non-invasive, diagnostic solutions for patients with chronic gastrointestinal disorders. The company headquarters are located at 1121 San Antonio Rd Suite D203, Palo Alto, CA 94303. For further information, please go to http://www.GTechMedical.com or send an email to info(at)gtechmedical(dot)com.

# # #

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/9/prweb9949535.htm


Source: prweb



comments powered by Disqus